RxDoctor Payments Data

Mai Anh Huynh, MD

Radiation Oncology · Boston, MANPI 1386908853

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Viewray Technologies Inc accounts for 77.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $5,891 and has fallen 90.3% since, to $572 in 2025.

$7,566in general payments, 2019–2025

Across 21 payments — averaging $360.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viewray Technologies Inc$6K
  • Novartis$1K
  • Icotec Medical Inc.$437
  • Siemens Medical Solutions USA, Inc.$171
$277,531in research payments, 2019–2025

Across 8 payments — averaging $34,691 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$240K
  • Viewray Technologies Inc$37K

What the payments were for

  • Consulting fees$3,47446%
  • Travel & lodging$2,27830%
  • Food & beverage$1,81424%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,566 in reported general payments places this provider in the 85th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$208,836
Medicare patients
181
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone33$81
Ondansetron Hcl12$34

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →